Literature DB >> 22123274

Antipsychotic drugs and the risk of hyperglycemia in older adults without diabetes: a population-based observational study.

Lorraine L Lipscombe1, Linda E Lévesque, Andrea Gruneir, Hadas D Fischer, David N Juurlink, Sudeep S Gill, Nathan Herrmann, Janet E Hux, Geoff M Anderson, Paula A Rochon.   

Abstract

OBJECTIVE: To determine whether current antipsychotic use among older persons without diabetes is associated with a higher risk of hospital visits for hyperglycemia, as previous studies in this population have yielded conflicting results. DESIGN, SETTING AND PARTICIPANTS: A nested case-control study within a population-based cohort of persons aged 66 years or older without diabetes, who initiated antipsychotic therapy between April 1, 2002, and March 31, 2006. Cohort members were identified using health databases from Ontario, Canada, and were followed from treatment start until March 31, 2007. MEASUREMENTS: Cases were patients with a hospital visit (emergency department visit or hospital admission) for hyperglycemia. We matched each case with up to 10 controls. We compared the risk of hyperglycemia among current antipsychotic users to that of remote users (discontinued > 180 days).
RESULTS: The cohort consisted of 44,121 subjects, mean age of 78.3 years, followed for a mean of 2.2 years. Compared to remote antipsychotic use, current treatment with any antipsychotic was associated with a significantly increased risk of hospital visits for hyperglycemia (adjusted odds ratio [aOR]: 1.52; 95% confidence interval [CI]: 1.07-2.17). The risk was elevated for both atypical (aOR: 1.44; 95% CI: 1.01-2.07) and typical (aOR: 2.86; 95% CI: 1.46-5.59) antipsychotic agents.
CONCLUSIONS: Current use of either atypical or typical antipsychotic agents was associated with a significantly increased risk of hospital visits for hyperglycemia among older persons without diabetes. These findings highlight the need for close glucose monitoring during antipsychotic therapy in older populations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22123274     DOI: 10.1097/JGP.0b013e318209dd24

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  5 in total

Review 1.  Atypical antipsychotic-induced metabolic disturbances in the elderly.

Authors:  Melanie Dawn Guenette; Araba Chintoh; Gary Remington; Margaret Hahn
Journal:  Drugs Aging       Date:  2014-03       Impact factor: 3.923

2.  Evaluation of the Impact of Corticosteroid Dose on the Incidence of Hyperglycemia in Hospitalized Patients with an Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Authors:  James M Baker; Heather A Pace; James B Ladesich; Stephen D Simon
Journal:  Hosp Pharm       Date:  2016-04

3.  Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies.

Authors:  Miquel Bernardo; Fernando Rico-Villademoros; Clemente García-Rizo; Rosa Rojo; Ricardo Gómez-Huelgas
Journal:  Adv Ther       Date:  2021-04-07       Impact factor: 3.845

4.  Comparing the cohort design and the nested case-control design in the presence of both time-invariant and time-dependent treatment and competing risks: bias and precision.

Authors:  Peter C Austin; Geoffrey M Anderson; Candemir Cigsar; Andrea Gruneir
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-06-01       Impact factor: 2.890

5.  History of coronary heart disease increased the mortality rate of patients with COVID-19: a nested case-control study.

Authors:  Tian Gu; Qiao Chu; Zhangsheng Yu; Botao Fa; Anqi Li; Lei Xu; Ruijun Wu; Yaping He
Journal:  BMJ Open       Date:  2020-09-17       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.